Inventor
FREIER SUSAN M
US255 patents
⚠️ This page may combine multiple inventors who share the name “FREIER SUSAN M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ISIS PHARMACEUTICALS INC
26 patentsUS7399853B2Jul 15, 2008
Modulation of glucagon receptor expression
ISIS PHARMACEUTICALS INC105 citations99
US7217572B2May 15, 2007
Modulation of HIF1α and HIF2α expression
ISIS PHARMACEUTICALS INC139 citations99
US5576208ANov 19, 1996
Antisense oligonucleotide inhibition of the RAS gene
ISIS PHARMACEUTICALS INC151 citations99
US7951934B2May 31, 2011
Compositions and their uses directed to huntingtin
ISIS PHARMACEUTICALS INC51 citations98
US7563884B2Jul 21, 2009
Antisense modulation of PTP1B expression
ISIS PHARMACEUTICALS INC67 citations98
US7339051B2Mar 4, 2008
Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
ISIS PHARMACEUTICALS INC158 citations98
US7235653B2Jun 26, 2007
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
ISIS PHARMACEUTICALS INC117 citations98
US6383808B1May 7, 2002
Antisense inhibition of clusterin expression
ISIS PHARMACEUTICALS INC99 citations98
US6287860B1Sep 11, 2001
Antisense inhibition of MEKK2 expression
ISIS PHARMACEUTICALS INC334 citations98
US6210892B1Apr 3, 2001
Alteration of cellular behavior by antisense modulation of mRNA processing
ISIS PHARMACEUTICALS INC358 citations98
US9057066B2Jun 16, 2015
Compositions and their uses directed to huntingtin
ISIS PHARMACEUTICALS INC37 citations97
US8952145B2Feb 10, 2015
Compositions and their uses directed to huntingtin
ISIS PHARMACEUTICALS INC23 citations96
US7902163B2Mar 8, 2011
Antisense modulation of superoxide dismutase 1, soluble expression
ISIS PHARMACEUTICALS INC34 citations96
US7803930B2Sep 28, 2010
Antisense modulation of apolipoprotein B-expression
ISIS PHARMACEUTICALS INC40 citations96
US7678895B2Mar 16, 2010
Antisense modulation of superoxide dismutase 1, soluble expression
ISIS PHARMACEUTICALS INC28 citations96
US7622455B2Nov 24, 2009
Methods for slowing familial ALS disease progression
ISIS PHARMACEUTICALS INC42 citations96
US7321828B2Jan 22, 2008
System of components for preparing oligonucleotides
ISIS PHARMACEUTICALS INC216 citations96
US6455308B1Sep 24, 2002
Antisense modulation of serum amyloid A4 expression
ISIS PHARMACEUTICALS INC69 citations96
US6359124B1Mar 19, 2002
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
ISIS PHARMACEUTICALS INC67 citations96
US5965722AOct 12, 1999
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
ISIS PHARMACEUTICALS INC53 citations96
US5837449ANov 17, 1998
Compositions and methods for modulating β-amyloid
ISIS PHARMACEUTICALS INC68 citations96
US5582986ADec 10, 1996
Antisense oligonucleotide inhibition of the ras gene
ISIS PHARMACEUTICALS INC75 citations96
US9765338B2Sep 19, 2017
Modulation of dystrophia myotonica-protein kinase (DMPK) expression
ISIS PHARMACEUTICALS INC67 citations95
US7176303B2Feb 13, 2007
Modulation of STAT5 expression
ISIS PHARMACEUTICALS INC42 citations95
US9382540B2Jul 5, 2016
Compositions and methods for modulating angiopoietin-like 3 expression
ISIS PHARMACEUTICALS INC13 citations93
US9061044B2Jun 23, 2015
Modulation of transthyretin expression
ISIS PHARMACEUTICALS INC14 citations93
BENNETT C FRANK
10 patentsUS8133876B2Mar 13, 2012
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
BENNETT C FRANK44 citations99
US8110558B2Feb 7, 2012
Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
BENNETT C FRANK61 citations99
US8106025B2Jan 31, 2012
Method for inhibiting the activity of mir-155
BENNETT C FRANK45 citations99
US8546350B2Oct 1, 2013
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
BENNETT C FRANK35 citations98
US8258109B2Sep 4, 2012
Compositions and methods for modulation of LMNA expression
BENNETT C FRANK44 citations98
US8697663B2Apr 15, 2014
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
BENNETT C FRANK26 citations96
US8957040B2Feb 17, 2015
Selective reduction of allelic variants
BENNETT C FRANK42 citations93
US8946179B2Feb 3, 2015
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
BENNETT C FRANK12 citations93
US8809294B2Aug 19, 2014
Method of inhibiting miR-33 using a modified oligonucleotide
BENNETT C FRANK7 citations93
US8765701B2Jul 1, 2014
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
BENNETT C FRANK7 citations93
IONIS PHARMACEUTICALS INC
7 patentsUS10221414B2Mar 5, 2019
Compositions for modulating C9ORF72 expression
IONIS PHARMACEUTICALS INC14 citations94
US9695418B2Jul 4, 2017
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
IONIS PHARMACEUTICALS INC36 citations94
US9567587B2Feb 14, 2017
Antisense modulation of GCCR expression
IONIS PHARMACEUTICALS INC30 citations94
US10006027B2Jun 26, 2018
Methods for modulating Ataxin 2 expression
IONIS PHARMACEUTICALS INC21 citations93
US9914922B2Mar 13, 2018
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
IONIS PHARMACEUTICALS INC14 citations93
US9683235B2Jun 20, 2017
Compositions for modulating Tau expression
IONIS PHARMACEUTICALS INC14 citations93
US9353372B2May 31, 2016
Compositions and their uses directed to huntingtin
IONIS PHARMACEUTICALS INC16 citations93
REGULUS THERAPEUTICS INC
2 patentsFREIER SUSAN M
2 patentsSWAYZE ERIC E
1 patentGENZYME CORP
1 patentLOLLO BRIDGET
1 patentShowing the top 50 of 255 patents by PatentIndex Score.